Christophe Courtine

Mr. Christophe Courtine

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2026
Verified
Other
Open access
SVSri Vemulamanda
Sri Vemulamanda
AKAditi Kothari
Aditi Kothari
LCLoris De cecco
Loris De cecco
SKSulgi Kim
Sulgi Kim
AKAditi Kulkarni
Aditi Kulkarni
TSTravis P. Schrank
Travis P. Schrank
Supplemental Figure 6. Survival Plot. Prognostic Value of NanoString NAC Classifier Measurements. In Figure 4, PFS was shown for (E) all patients and (F) de-escalation candidates in UNC and E1308 cohorts (non-smoker,

1 July 2026
Verified
Other
Open access
SVSri Vemulamanda
Sri Vemulamanda
AKAditi Kothari
Aditi Kothari
LCLoris De cecco
Loris De cecco
SKSulgi Kim
Sulgi Kim
AKAditi Kulkarni
Aditi Kulkarni
TSTravis P. Schrank
Travis P. Schrank
Supplemental Table 4. Association of NF-κB high and low groups with clinical parameters in combined UNC &E1308 cohorts (1) as pictured in Figure 4D-E. P-value assessed by χ2 test, except for age (assessed with t-test).

1 July 2026
Verified
Other
Open access
SVSri Vemulamanda
Sri Vemulamanda
AKAditi Kothari
Aditi Kothari
LCLoris De cecco
Loris De cecco
SKSulgi Kim
Sulgi Kim
AKAditi Kulkarni
Aditi Kulkarni
TSTravis P. Schrank
Travis P. Schrank
Supplemental Figure 5. NF-κB pathway mutations are found in cases with high NF-κB scores. A) NanoString NF-κB expression scores and NF-κB pathway mutational data from UNC cohort where both metrics were available. B) Non-linear least squares fit of mono-exponential function relating NanoString and RNAseq data. This fit was used to transpose the threshold defined by NanoString to the RNAseq data, where 3 more cases were available.

1 July 2026
Verified
Other
Open access
SVSri Vemulamanda
Sri Vemulamanda
AKAditi Kothari
Aditi Kothari
LCLoris De cecco
Loris De cecco
SKSulgi Kim
Sulgi Kim
AKAditi Kulkarni
Aditi Kulkarni
TSTravis P. Schrank
Travis P. Schrank
Supplemental Figure 2. UMAP dimensional reduction plot with malignancy probabilities from scMalignantFinder. Low probability predictions (<0.5) were imputed with to a value of 0.5 for visual clarity.

16 January 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
PTPradham Tanikella
Pradham Tanikella
WNWilliam Nenad
William Nenad
CCChristophe Courtine
Christophe Courtine
YDYifan Dai
Yifan Dai
QDQingying Deng
Qingying Deng
DWDi Wu
Di Wu
Background/Objectives: Head and neck cancer (HNC) represents the seventh most common cancer diagnosis globally, yet current treatments, including surgery, radiation, and immunotherapy, have shown limited improvement in outcomes. Drug repurposing offers a cost-effective strategy to identify new therapeutic options by leveraging existing medications with known safety profiles. Within this study we developed the GARD pipeline ( G enomic A lteration-based R epurposing for D rugs), designed to uncover repurposing candidates for HNC using genomic and network-based approaches. Methods: GARD integrates multi-omics data from The Cancer Genome Atlas (TCGA), including copy number variation (CNV) and somatic mutations (SOM). The cohort was stratified by human papillomavirus (HPV) status. Risk-associated genes were identified and then expanded via high-confidence protein–protein interaction (PPI) networks. Top candidate genes were filtered through comprehensive analysis of publicly available literature data in PubMed using LLM to validate the relationship between the identified genes and HNC. The validated top risk genes and their network-expanded neighbors were mapped against DrugBank, and through statistical significance testing, established significant drug-gene associations. Results: Significant genes associated with HNC, inferred by genomics alteration, were identified across HPV-positive and HPV-negative subgroups, such as PIK3CA, SOX2, TP53, EIF4G1, TLR7, CLDN1, PRKCI, and EPHA2. Further expansion through the PPI network identified other targetable genes such as EGFR, ERBB2, and the FGFRs. Literature based validation efforts ensured provided confidence in the gene-disease association. Drug-gene mapping revealed candidates spanning already in clinical trials for HNC (e.g. Afatinib, Cabozantinib, Dasatinib, Brigatinib, Lenvatinib, Capivasertib, Erdafitinib) and emerging or repurposing candidates (Amuvatinib, XL765 (Voxtalisib), Golotimod, Artenimol, Quercetin, and Acetylsalicylic Acid), offering opportunities for precision repurposing. Conclusions: The GARD pipeline demonstrates a genomics-driven, network-informed framework for systematic drug repurposing in HNC. HPV stratification enhances precision, literature-based validation strengthens confidence, and integrated drug mapping enables refinement of existing therapies and discovery of novel candidates for personalized treatment strategies. Code Availability: The full implementation of the GARD pipeline, including preprocessing scripts, statistical analysis modules, and visualization tools, is publicly available on GitHub at: https://github.com/pvtanike/Genomic-Landscape-Based-Drug-Repurposing.git Simple Summary: Head and neck cancer (HNC) is among the most prevalent and challenging cancers world-wide. Developing new drugs is expensive and time-consuming, so this study explored a faster, cost-effective approach utilizing existing medications with established safety profiles: drug repurposing. We developed the GARD pipeline ( G enomic A lteration-based R epurposing for D rugs), which utilizes large-scale genomic data from The Cancer Genome Atlas (TCGA) to identify key genomics changes in HNC. These genes are expanded through protein–protein interaction networks to capture related pathways and then validated using evidence from thousands of PubMed articles extracted by large language model (LLM) tools. Finally, validated genes are matched with drugs using the DrugBank database. This approach uncovered both known cancer drugs and promising new candidates. These included targeted therapies such as Fostamatinib, Nintedanib, Brigatinib, Regorafenib, and Lenvatinib, as well as emerging compounds like Artenimol, Quercetin, and Acetylsalicylic Acid (Aspirin). Through a combination of genomic analysis, network expansion, and literature validation, the GARD pipeline offers a powerful way to accelerate personalized cancer treatments while reducing cost and development time.

26 February 2026 in Cancers
Verified
Journal Article
Open access
PDF file
PTPradham Tanikella
Pradham Tanikella
WNWilliam Nenad
William Nenad
CCChristophe Courtine
Christophe Courtine
YDYifan Dai
Yifan Dai
QDQingying Deng
Qingying Deng
DWDi Wu
Di Wu
Background/Objectives: Head and neck cancer (HNC) represents the seventh most common cancer diagnosis globally, yet current treatments, including surgery, radiation, and immunotherapy, have shown limited improvement in outcomes. Drug repurposing offers a cost-effective strategy to identify new therapeutic options by leveraging existing medications with known safety profiles. Within this study, we developed the GARD pipeline (Genomic Alteration-based Repurposing for Drugs), designed to uncover repurposing candidates for HNC using genomic and network-based approaches. Methods: GARD integrates multi-omics data from The Cancer Genome Atlas (TCGA), including copy number variation (CNV) and somatic mutations (SOM). The cohort was stratified by human papillomavirus (HPV) status. Risk-associated genes were identified and then expanded via high-confidence protein–protein interaction (PPI) networks. Top candidate genes were filtered through comprehensive analysis of publicly available literature data in PubMed using LLMs to validate the relationship between the identified genes and HNC. The top risk genes and their network-expanded neighbors were mapped against DrugBank, and through statistical significance testing and literature validation, established significant drug–gene associations. Results: Significant genes associated with HNC, inferred by genomics alteration, were identified across HPV-positive and HPV-negative subgroups, such as PIK3CA, SOX2, TP53, EIF4G1, TLR7, CLDN1, PRKCI, and EPHA2. Further expansion through the PPI network identified other targetable genes such as EGFR, ERBB2, and the FGFRs. Literature-based validation efforts ensured confidence in the gene–disease association. Drug–gene mapping revealed candidates spanning those already in clinical trials for HNC (e.g., Afatinib, Cabozantinib, Dasatinib, Brigatinib, Lenvatinib, Capivasertib, and Erdafitinib) and emerging or repurposing candidates (Amuvatinib, XL765 (Voxtalisib), Golotimod, Artenimol, Quercetin, and Acetylsalicylic Acid), offering opportunities for precision repurposing. Conclusions: The GARD pipeline demonstrates a genomics-driven, network-informed framework for systematic drug repurposing in HNC. HPV stratification enhances precision, literature-based validation strengthens confidence, and integrated drug mapping enables refinement of existing therapies and discovery of novel candidates for personalized treatment strategies. Code Availability: The full implementation of the GARD pipeline, including preprocessing scripts, statistical analysis modules, and visualization tools, is publicly available on GitHub.